5-fluorouracil + cyclophosphamide + pirarubicin

This drug is a combination chemotherapy regimen consisting of three agents: 5-fluorouracil, cyclophosphamide, and pirarubicin. It is commonly referred to as the FPC regimen. The combination is primarily used as adjuvant or front-line chemotherapy for breast cancer, including both early-stage (postoperative) and metastatic disease. - **5-fluorouracil** is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis and leading to cell death in rapidly dividing cells. - **Cyclophosphamide** is an alkylating agent that crosslinks DNA strands, preventing cell division and causing apoptosis in cancer cells. - **Pirarubicin** is an anthracycline antibiotic structurally related to doxorubicin; it intercalates into DNA and inhibits topoisomerase II activity, resulting in inhibition of DNA replication and repair. The FPC regimen has demonstrated efficacy comparable to other anthracycline-based regimens (such as those containing epirubicin or doxorubicin), with some studies suggesting a favorable toxicity profile regarding alopecia but with notable risks of myelosuppression and cardiotoxicity[2][3][5][6]. The main indications are for breast cancer treatment—both advanced/metastatic settings and postoperative adjuvant therapy.

Other names

FPCfluorouracil/pirarubicin/cyclophosphamide